괫ͳϰӭ
»2019ʮ      Ϊҳ      ղرվ
瓒崇悆姣斿垎棰勬祴鏈€鍑嗙殑浜
Դ    ڣ20200809 13:20    СʿͼƬĶһҳ
ԭ⣺瓒崇悆姣斿垎棰勬祴鏈€鍑嗙殑浜й±仯ʮû һʵ

瓒崇悆姣斿垎棰勬祴鏈€鍑嗙殑浜ѶǽЩӦõ忹жУȡЧ⽫¸Ĺʱ䡢ߵĹǿԼͥ໥š˹316յ磨Уίͳ޽17賿5ʱίȫʵиʩ¹ڲӡ

ظ˱ʾйڻȨͶʵĻ̽ծתģʽͨµĽ׽ṹծתг·չ𡿡ҩ󡿡ɡڡ졿ȡ񡿡áۡšơءλ⡿һΥҡ¢ϡ򡿡ҩƷࡿܡࡿءɡ桿⡿á񡿡᡿ǰԡʳƷաáƷȡʡС

ĻԹʾ̾͹Ļ5ڱ³ʵʩ״̬һ£ʵڲ֪↑ʼαը˾

ҪҲҪڳ47ӵݽУջ˽˵Աһһֵijɾ͡±ѩǽ19ĩ20ͳ̽ȴΪٻɾۼصķǷΪǰ룬ѹǷĵ£Ѿʮã

ͬʱĻŬŻϺ»лϣ¬ɭڽйͳĻ֪ʶƳлʳ⿲ףתҴԺйͯԺԺȻֱƵḻڵĻǶйĻ˽⡣罻ýܷΧġýָı³̨ġOstrscandidatoschinesessoaSinovac,oInstitutodeProdutosBiolgicos/SinopharmdeWuhaneoInstitutodeProdutosBiolgicos/SinopharmdeBeijing,revelouMichaelRyan,diretorexecutivodoProgramadeEmergnciasdaSadedaOrganizaoMundialdaSade(OMS),svacinascandidatasestosendodesenvolvidaspelaUniversidadedeOxford/AstraZeneca,pelaModerna/NIAIDepelaBioNTech/FosunPharma/Pfizer,fase3,apsexperimentospreliminaresqueseconcentraramnasegurana,naimunogenicidadeenarespostaimunolseasvacinaspodem"protegerumgrandenmerodepessoasduranteumperododetempoprolongado".Noentanto,"afase3noquerdizerqueestamosquasel",disseele,pois"nohgarantiadequequalquerumadestasseiscandidatasvainostrazerasoluo".Aotodo,165candidatosavacinasjiniciaramalgumasformasdetestes,e26delesrealizaramestudosclnicos,deacordocomosregistrosdaOMS.ǵãһ¥ס˼ңϴϲҪŶӣӼϡ롰һҲϡ桱ذ塢¥ݶദգȥ֨ѽ졣

зϸƷڣǹΪھƷֹͣͨƷڸȨ

瓒崇悆姣斿垎棰勬祴鏈€鍑嗙殑浜

亶Դˣרұʾһǿ˽ļܺҵԲ⣬ͨͶ߶ԣҪϸĶͬͶʷաڳͷʼ׷ײѧԺ˵ֶ֧壬ǰ

ά˹ֽϣάDz翪չѧĹңĿǰѧԺͿӿάǹܻӭʮּںѧĽһΪѺõ춨ʯ߽73ĽĿСԺǰһƬ԰ﳤ齷عϡȡ˵߲ߣ¡

||202085峿񻷺ͼɽΪɨĹǴѺӶ԰СһߡʺЭ㣬еĽÿӰ򺽰480˿ͣ2000Ԫֱ֧ʧߴԪ

㣩˹911յ磨УΪףл񹲺͹70ί45꣬פίʹί⽻Ͼٰ조һһ·6ͨͼƬչ̣ܱ߽߳٣һЩײһھкܡǰйפʹפԼ¬аͶһͬ조ʿߺϵֻᡱ2006꣬ǹܹ˾ܹʦʤ֣еر꽨¹ŵʩơ

ͬʱþйҲӻԾ򵱵ʾõڵĹذͰڹ˴޹ں󲿷ϰճҪгֳƿȹߣȽŲ򲻻ʻйߵˡѧʿֻ·̾ûйdzžҽ׷ѵġ·ͬģдׯֵоҵתƾҵƿƳ{˵ѵĿǰв˴ξ5000ңÿ˶лᡣ

Щƻ9ͨ޶ЧԺ͸ɡ2017822ʡ߼Ժύ201931գʡ߼Ժ202079ս˹ͥµĸţھ˵ŮӢϲȢƽ˳ϲͷȺʱϵĸŮʮȻչšɵܵܡԥŵƽ˳ʮ󣬳ƽ˳ų

ȵƼ
ÿ
ȵƼ
ͼ˵
༭Ƽ

վռڻȨԭСַİȨ뼴ʱϵɾ䣺wabing@126.com

2019꣬ջ񡭡 Copyright © 2016 jpzgs.com All Rights Reserved ICPICP14035461-4